Wallace Rheumatic Study Center LLC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$70,089	10
2024	Research	$98,588	3
2023	Research	$112,278	36
2022	Research	$63,989	5
2021	Research	$41,542	6
2020	Research	$21,193	13
2019	Research	$64,817	34

Breakdown

Who paid Research payments · program years 2019–2025

Ucb SA $279,219 9 payments
GlaxoSmithKline, LLC. $85,641 20 payments
EMD Serono, Inc. $78,091 40 payments
AstraZeneca UK Limited $16,176 3 payments
Kiniksa Pharmaceuticals, Ltd. $13,368 35 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $168,153 4 payments
A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus $111,066 5 payments
A 5-Year Prospective Observational Registry to Assess Adverse Events O $43,490 13 payments
A Phase 4, Multicenter, Prospective, Open-Label Study Describing the E $42,151 7 payments
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) $36,013 10 payments
Ms 200527-0018 $34,939 16 payments
Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) $16,176 3 payments
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor $12,564 15 payments
Ms200527-0018 $7,139 14 payments
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor $804 20 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.